VKTX Earnings & Financial Statements
Viking Therapeutics, Inc.
$28.72
+$0.34(+1.18%)
39
Overall
60
Value
27
Tech
31
Quality
Market Cap
$3.57B
Volume
2.85M
52W Range
$25.77 - $43.15
Target Price
$92.00
VKTX earnings and financial statements: Viking Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VKTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$393.34M | -$150.92M | -$100.83M | -$70.36M | -$55.68M |
| EBITDA | -$392.91M | -$150.56M | -$100.62M | -$90.61M | -$55.39M |
| Net income | -$359.64M | -$109.96M | -$85.89M | -$68.87M | -$54.99M |
| EPS (diluted) | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $715.73M | $908.32M | $368.49M | $168.53M | $210.66M |
| Total liabilities | $76.67M | $28.04M | $20.07M | $23.21M | $8.78M |
| Shareholders’ equity | $639.06M | $880.28M | $348.42M | $145.32M | $201.88M |
| Cash and equivalents | $165.81M | $26.68M | $55.52M | $36.63M | $26.37M |
| Long-term debt | - | $630.0K | $936.0K | $1.26M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$278.69M | -$87.79M | -$73.38M | -$48.40M | -$47.59M |
| Free cash flow | -$278.69M | -$87.79M | -$73.38M | -$48.40M | -$47.59M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VKTX | $28.72 | +1.2% | 2.85M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Viking Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW